CARsgen Therapeutics Holdings Limited Announces Acceptance of Key Research Results at 2026 EHA Annual Congress

Overview

CARsgen Therapeutics Holdings Limited (“CARsgen” or the “Company”) has made a significant announcement that may have important implications for shareholders and potential investors. The Company revealed that its research findings on two of its allogeneic CAR T-cell therapies, CT0596 and CT1190B, have been accepted for poster presentation at the prestigious 2026 Annual Congress of the European Hematology Association (EHA).

Key Highlights for Investors

• Poster Presentation at 2026 EHA Annual Congress: The research results of the investigator-initiated trials (IITs) for CT0596 and CT1190B will be presented at one of the world’s most influential hematology conferences, signaling recognition and validation from the scientific community.
• Details to be Released: Abstracts and further details regarding these studies will be made public after May 12, 2026, 15:30 CEST. Investors are advised to monitor the Company’s website for updates.
• Key Pipeline Assets:
  • CT0596: An allogeneic CAR T-cell therapy targeting BCMA, developed using CARsgen’s proprietary THANK-u Plus™ platform. Currently under IITs for relapsed/refractory multiple myeloma (R/R MM) and plasma cell leukemia (PCL). Early results suggest favorable tolerability and encouraging efficacy, with plans to initiate Phase Ib clinical trials for R/R MM and primary PCL in 2026.
  • CT1190B: A dual-targeted allogeneic CAR T-cell therapy against CD19/CD20, also based on the THANK-u Plus™ platform. Ongoing trials include IITs for relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL), moderate-to-severe refractory systemic lupus erythematosus (SLE), and refractory/progressive systemic sclerosis (SSc). Phase Ib clinical trials for R/R B-NHL are scheduled for 2026.
• Potential Indications Expansion: Both therapies are being investigated for broader indications, including autoimmune diseases in addition to hematologic malignancies.
• Technological and Commercial Strengths: CARsgen has full-spectrum capabilities from target discovery and preclinical research through clinical development and commercial production. The Company is also focused on improving the safety and efficacy of CAR T-cell therapies, especially in solid tumors, and reducing overall treatment costs.

Potential Price-Sensitive Information

• Market Recognition: The acceptance of CARsgen’s data at EHA 2026 is a noteworthy milestone. This recognition may enhance the Company’s credibility, attract strategic partners, and potentially influence the Company’s valuation and share price.
• Clinical Progression: The planned initiation of Phase Ib trials for both CT0596 and CT1190B in 2026 underscores the advancement of CARsgen’s pipeline, which could be perceived positively by the market.
• Broader Indication Potential: Expansion of the pipeline into autoimmune diseases, alongside cancer, opens new market opportunities and could materially affect the Company’s long-term prospects and share value.

Risks and Cautionary Notes

• Development Risks: CARsgen explicitly cautions that there is no guarantee that CT0596 and CT1190B will successfully complete development or be commercialized.
• Forward-Looking Uncertainties: The Company notes that all forward-looking statements are subject to significant risks and uncertainties, and actual outcomes may differ materially from projections.
• Investor Caution: Shareholders and potential investors are strongly advised to exercise caution when trading shares, given the inherent uncertainties in clinical development and commercialization.

About CARsgen Therapeutics Holdings Limited

CARsgen is a biopharmaceutical company focused on developing innovative CAR T-cell therapies for unmet clinical needs in hematologic malignancies, solid tumors, and autoimmune diseases. The Company’s integrated platform and proprietary technologies enable them to develop globally competitive products with improved safety, efficacy, and cost profiles.

Board of Directors

As of the announcement date (April 27, 2026), the board comprises Dr. Zonghai Li (Chairman), Dr. Huamao Wang, Dr. Hua Jiang (Executive Directors), Mr. Huaqing Guo, Mr. Ronggang Xie (Non-executive Directors), Dr. Guangmei Yan, Ms. Xiangke Zhao, and Dr. Wen Zhou (Independent Non-executive Directors).

Disclaimer: This article is for informational purposes only and does not constitute investment advice. All forward-looking statements are subject to risks and uncertainties. Investors should review official company materials and exercise caution when making investment decisions regarding CARsgen Therapeutics Holdings Limited.

View CARSGEN-B Historical chart here